This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nachman, P. H. Articles by Martin, J. Search for Related Content Social Bookmarking                         What's this?

Developments in the Immunotherapy of Glomerular Disease

Division of Nephrology and Hypertension, Department of Medicine, University of North Carolina, Chapel Hill, Patrick_Nachman{at}med.unc.edu

Jeffrey Martin, RPh, MD

Division of Nephrology and Hypertension, Department of Medicine, University of North Carolina, Chapel Hill

Glomerular diseases span a broad spectrum of clinical syndromes, with varied clinical manifestations, underlying etiologies, and pathogenic mechanisms. They can be secondary to underlying infectious, toxic, environmental, or drug exposures, or present as "primary entities." In the latter case, most glomerular diseases are thought to be due to autoimmune dysregulation, and their treatment is primarily immunosuppressive. The armamentarium for immunomodulation includes corticosteroids, alkylating agents, anti-metabolites, calcineurin inhibitors, and new biological agents designed to block specific inflammatory pathways. The choice of therapy for an individual patient must be based on the specific character of the glomerular disease and its acuity and severity, as well as the patient’s comorbidities, history of prior exposure to immunosuppressive drugs, and risk factors for developing complications of the disease or its treatment. The complexities of such therapy can best be addressed by an experienced team of care givers in which the clinical pharmacist can help minimize, if not eliminate, potential sources of drug induced toxicities and adverse effects. This article will describe the major agents and modalities used in the management of the most common glomerular diseases.

Key Words: glomerular diseases • drug treatments • immunotherapy

Journal of Pharmacy Practice, Vol. 15, No. 6, 472-489 (2002)
DOI: 10.1177/089719002237666


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?